JCR Pharmaceuticals Co., Ltd.
Other OTCTotal Valuation
JCR Pharmaceuticals Co., Ltd. carries a market capitalization of 383.67M, placing it among publicly traded companies globally. Its enterprise value stands at 94.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 383.67M |
| Enterprise Value | 94.83B |
Share Statistics
JCR Pharmaceuticals Co., Ltd. currently has 125.50M shares outstanding.
| Shares Outstanding | 125.50M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
JCR Pharmaceuticals Co., Ltd. trades at a trailing price-to-earnings ratio of 332.06. The price-to-sales ratio is 4.53, and the price-to-book ratio stands at 1.85.
| PE Ratio | 332.06 |
| PS Ratio | 4.53 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.57 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, JCR Pharmaceuticals Co., Ltd. trades at an EV/EBITDA multiple of 149.57 and an EV/FCF ratio of 922.83. The EV/Sales ratio of 5.10 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 149.57 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.10 |
| EV / EBITDA | 149.57 |
| EV / EBIT | 149.57 |
| EV / FCF | 922.83 |
Financial Position
JCR Pharmaceuticals Co., Ltd. maintains a current ratio of 1.65, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 49.80, indicating elevated leverage, while an interest coverage ratio of 13.78 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.65 |
| Quick Ratio | 0.54 |
| Debt / Equity | 49.80 |
| Debt / EBITDA | 44.81 |
| Interest Coverage | 13.78 |
Financial Efficiency
| Return on Equity (ROE) | 0.55 |
| Return on Assets (ROA) | 0.24 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | 7.43 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.27 |
Taxes
Over the trailing twelve months, JCR Pharmaceuticals Co., Ltd. has paid -153.00M in income taxes, reflecting an effective tax rate of 135.06.
| Income Tax | -153.00M |
| Effective Tax Rate | 135.06 |
Stock Price Statistics
JCR Pharmaceuticals Co., Ltd.'s stock has declined approximately -31.18162% over the past 52 weeks. The 50-day moving average sits at 4.11, while the 200-day moving average is 4.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.18162% |
| 50-Day Moving Average | 4.11 |
| 200-Day Moving Average | 4.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, JCR Pharmaceuticals Co., Ltd. generated 18.60B in revenue and converted that into 254.00M in net income, yielding earnings per share of 2.22. EBITDA reached 634.00M, while operating income came in at 634.00M.
| Revenue | 18.60B |
| Gross Profit | 12.86B |
| Operating Income | 634.00M |
| Pretax Income | 124.00M |
| Net Income | 254.00M |
| EBITDA | 634.00M |
| EBIT | 634.00M |
| Earnings Per Share (EPS) | 2.22 |
Balance Sheet
JCR Pharmaceuticals Co., Ltd. holds 18.27B in cash and equivalents against 28.41B in total debt, resulting in a net debt position of 10.14B. Total book value stands at 45.58B, with working capital of 22.17B providing operational flexibility.
| Cash & Cash Equivalents | 18.27B |
| Total Debt | 28.41B |
| Net Debt | 10.14B |
| Equity (Book Value) | 45.58B |
| Book Value Per Share | 365.08 |
| Working Capital | 22.17B |
Margins
JCR Pharmaceuticals Co., Ltd. operates with a gross margin of 69.14, reflecting its pricing power and cost economics. The operating margin of 3.41 and net profit margin of 1.37 provide insight into operational efficiency.
| Gross Margin | 69.14 |
| Operating Margin | 3.41 |
| Pretax Margin | 0.67 |
| Profit Margin | 1.37 |
| EBITDA Margin | 3.41 |
Scores
JCR Pharmaceuticals Co., Ltd. posts an Altman Z-Score of 2.03, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.03 |